Illustration of a meditation group with mixed expressions of calm and distress, alongside a researcher, representing study on meditation side effects.
Picha iliyoundwa na AI

Study details potential side effects of meditation practice

Picha iliyoundwa na AI
Imethibitishwa ukweli

New research indicates that while meditation is widely promoted for mental health, a substantial share of practitioners report unpleasant experiences, with about a third finding them distressing. Psychologist Nicholas Van Dam and colleagues say the findings underscore the need for clearer informed consent in mindfulness programs.

A study published in Clinical Psychological Science reports that meditation can produce unwanted experiences for some practitioners, including anxiety, feelings of disembodiment, and—in a minority of cases—functional impairment. The team, led by Nicholas Van Dam of the University of Melbourne, found that nearly 60% of meditators reported at least one side effect and roughly 30% described effects as challenging or distressing. About 9% reported impairment in day-to-day functioning. (sciencedaily.com)

Researchers surveyed nearly 900 adults across the United States in a cross-sectional, population-based study designed to approximate the U.S. meditator population using Centers for Disease Control and Prevention data. Participants ranged from beginners to advanced practitioners. To capture experiences systematically, the team used a 30-item checklist that asked respondents to rate intensity, whether experiences felt positive or negative, and whether they affected daily functioning. (psychologicalscience.org)

The study identified several risk factors. Individuals reporting psychological symptoms or distress in the prior 30 days were more likely to report adverse effects. Attendance at residential meditation retreats—often long and intensive—was also associated with a higher likelihood of reporting at least one effect that impaired functioning. In the sample, 58.4% reported at least one adverse effect on a standardized inventory, about 31% reported challenging or distressing experiences, and 9.1% reported functional impairment. (psychologicalscience.org)

“This is the kind of research that is done at the very beginning of developing any new treatment intervention program,” Van Dam said, noting that prior estimates of adverse effects vary widely—from about 1% in a 2018 review of randomized trials to as high as two thirds in some studies. The lower figure comes from a systematic review of mindfulness-based programs that also highlighted limited adverse-event monitoring, while higher estimates have been reported in work by Willoughby Britton and colleagues. (psychologicalscience.org)

Van Dam emphasized that the goal is awareness, not alarm. “Our conclusions are not that people should be terrified, or people should not try meditation. It’s really that we think that we should do a better job of providing informed consent,” he said, comparing the approach to how risks are disclosed before surgery or exposure therapy. He added that more longitudinal research is needed to clarify causality. “These practices are not for everyone,” he said. “If they’re not working, it might be because it’s just not a good match.” (psychologicalscience.org)

Makala yanayohusiana

UCSF researcher Jennifer Mitchell in a lab examining MM120, an LSD-based drug for treating generalized anxiety disorder.
Picha iliyoundwa na AI

UCSF researchers test LSD-based MM120 for generalized anxiety disorder

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

UCSF neuroscientist Jennifer Mitchell and collaborators are evaluating MM120, a pharmaceutical form of LSD, as a potential treatment for generalized anxiety disorder. A randomized clinical trial published in JAMA found that a single dose reduced anxiety symptoms versus placebo, with benefits persisting up to 12 weeks in the optimal dose group, according to the study and the drug’s sponsor.

A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.

Imeripotiwa na AI

A study published in Psychological Bulletin warns that excessive consumption of short videos on platforms like TikTok and Instagram impacts users' attention, mental health, and cognitive capacity, particularly among young people and adults. The research highlights how this format promotes superficial information processing, leading to mental fatigue and potential addictions. While the analysis has limitations, it calls for greater oversight in digital consumption.

A small randomized, double-blind trial suggests that MRI-based measures of brain structure may help predict which patients with major depressive disorder will show early symptom improvement after treatment with the traditional Chinese medicine Yueju Pill. In the four-day study, Yueju Pill and escitalopram were both associated with lower depression rating scores, but only Yueju Pill was linked to a rise in blood levels of brain-derived neurotrophic factor (BDNF).

Imeripotiwa na AI Imethibitishwa ukweli

Researchers behind a new review in Frontiers in Science argue that rapid progress in artificial intelligence and brain technologies is outpacing scientific understanding of consciousness, raising the risk of ethical and legal mistakes. They say developing evidence-based tests for detecting awareness—whether in patients, animals or emerging artificial and lab-grown systems—could reshape medicine, welfare debates and technology governance.

A research team from the University of Rochester, Harvard Medical School, and Boston Children’s Hospital reports that an inclusion-complex nano‑micelle formulation of cannabidiol, called CBD‑IN, rapidly reduced neuropathic pain in mice and did so without detectable balance, movement, or memory problems. The study, published online ahead of print in Cell Chemical Biology on November 7, 2025, suggests the effect did not depend on the classic CB1 or CB2 cannabinoid receptors.

Imeripotiwa na AI Imethibitishwa ukweli

A decades-long UK cohort study following 10,930 people born in 1970 found that children who showed more attention-deficit/hyperactivity disorder (ADHD) traits at age 10 had higher odds of multiple self-reported physical health conditions and physical health–related disability by age 46. The research, published in JAMA Network Open, suggests smoking, psychological distress and higher body mass index partly help explain the link, and highlights the need for better identification and support across adulthood.

 

 

 

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa